
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Pharmacol., 09 January 2024
Sec. Pharmacology of Anti-Cancer Drugs
Volume 14 - 2023 | https://doi.org/10.3389/fphar.2023.1322332
This article is a correction to:
A combination of metformin and epigallocatechin gallate potentiates glioma chemotherapy in vivo
A Corrigendum on
A combination of metformin and epigallocatechin gallate potentiates glioma chemotherapy in vivo
by Kuduvalli SS, Daisy PS, Vaithy A, Purushothaman M, Ramachandran Muralidharan A, Agiesh KB, Mezger M, Antony JS, Subramani M, Dubashi B, Biswas I, Guruprasad KP and Anitha TS (2023). Front. Pharmacol. 14:1096614. doi: 10.3389/fphar.2023.1096614
In the published article, there was an error in Table 1. The values of drug doses were inadvertently misrepresented during the final assembly of Table 1. The corrected Table 1 and its caption appear below.
TABLE 1. The concentration of each drug used in the treatment of animals both individually and in combination.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: glioma, metformin, epigallocatechin gallate (EGCG), molecular docking, quantum mechanics (QM), ROS-reactive oxygen species, PI3K/Akt/mTOR pathway
Citation: Kuduvalli SS, Daisy PS, Vaithy A, Purushothaman M, Muralidharan AR, Agiesh KB, Mezger M, Antony JS, Subramani M, Dubashi B, Biswas I, Guruprasad KP and Anitha TS (2024) Corrigendum: A combination of metformin and epigallocatechin gallate potentiates glioma chemotherapy in vivo. Front. Pharmacol. 14:1322332. doi: 10.3389/fphar.2023.1322332
Received: 16 October 2023; Accepted: 22 December 2023;
Published: 09 January 2024.
Edited by:
Jianqiang Xu, Dalian University of Technology, ChinaReviewed by:
Chandrabose Selvaraj, Alagappa University, IndiaCopyright © 2024 Kuduvalli, Daisy, Vaithy, Purushothaman, Muralidharan, Agiesh, Mezger, Antony, Subramani, Dubashi, Biswas, Guruprasad and Anitha. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: T. S. Anitha, dHNhbml0aGE2QHBvbmRpdW5pLmFjLmlu
†Present address: T. S. Anitha, Department of Biochemistry and Molecular Biology, Pondicherry University, Puducherry, India
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.